Radiation plus Anlotinib for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung cancer is locally advanced (has not spread to distant organs) and cannot be removed with surgery.
- Your cancer does not have certain genetic mutations (EGFR, ALK, ROS1).
- You have received at least 4 weeks of chemotherapy or chemo-immunotherapy without the cancer getting worse.
- Your tumor is located away from the main blood vessels of the lung and has no cavity inside it.
- You have no active bleeding from the lungs, and your liver, kidney, and urine tests are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This trial tests whether combining Anlotinib (a targeted drug that blocks tumor blood vessel growth) with whole-brain radiation can better control brain metastases in small cell lung cancer patients. It is for people with up to 10 brain tumors who have not had brain radiation before.
This trial tests combining anlotinib (a targeted drug that blocks tumor blood vessels) with standard chemotherapy for a rare type of advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combination helps people who haven't had treatment before.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.